Education and Training
Long-Term Follow-up Protocol
The main objective of this prospective, observational, long-term follow-up (LTFU) study is to evaluate the long-term safety profile of the gene therapy products evaluated by Krystal Biotech, Inc. which have a shared backbone of HSV-1, in participants who received at least one dose of investigational product (IP).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Eligibility
Inclusion Criteria:
- All adult and pediatric participants who received at least one gene therapy treatment
in a previous Krystal Biotech, Inc. sponsored study, and have discontinued or
completed the parent treatment protocol (which do not have the LTFU embedded into the
parent protocol), as applicable.
- Consent/Assent must be obtained by the participants (and, parental/legal
representative, when applicable) prior to any study-related data being collected.
- Participant is willing and able to adhere to the protocol requirements.
Exclusion Criteria:
- Participants who enroll into a non-Krystal Biotech, Inc. interventional gene therapy
clinical trial will be excluded from the study.
Ages Eligible for Study
6 Months - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Sinem Bagci
650-484-6878
I'm interested